within Pharmacolibrary.Drugs.ATC.J;

model J04AC51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.31666666666666665,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.00057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Isoniazid, in combination with other antimycobacterials (ATC J04AC51), is used for the treatment and prevention of tuberculosis. It is a first-line agent commonly combined with rifampicin, ethambutol, and pyrazinamide. These combinations are approved and remain standard of care for tuberculosis therapy globally.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters are given for a typical adult (age 18–65 years, both sexes) receiving isoniazid in combination regimen for tuberculosis; no published compartmental PK model specific to J04AC51 fixed combination product found.</p><h4>References</h4><ol><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=&quot;https://doi.org/10.1007/s40272-013-0017-5&quot;>10.1007/s40272-013-0017-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23529866/&quot;>https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Phaisal, W, et al., &amp; Chariyavilaskul, P (2022). Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection. <i>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</i> 122 725–732. DOI:<a href=&quot;https://doi.org/10.1016/j.ijid.2022.07.040&quot;>10.1016/j.ijid.2022.07.040</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35868608/&quot;>https://pubmed.ncbi.nlm.nih.gov/35868608</a></p></li><li><p>P Brock, A, et al., &amp; Peloquin, CA (2014). The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus). <i>Journal of veterinary pharmacology and therapeutics</i> 37(5) 472–479. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12119&quot;>10.1111/jvp.12119</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24684601/&quot;>https://pubmed.ncbi.nlm.nih.gov/24684601</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J04AC51;
